- Trials with a EudraCT protocol (35)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
35 result(s) found for: Protein methylation.
Displaying page 1 of 2.
EudraCT Number: 2021-006224-40 | Sponsor Protocol Number: AxGD | Start Date*: Information not available in EudraCT |
Sponsor Name:Instytut ,,Pomnik-Centrum Zdrowia Dziecka" | ||
Full Title: Evaluation of the safety and efficacy of ambroxol (ABX) use in Polish patients with Gaucher disease, presenting neuronopathic type (GD type III, GD3) resulting from homozygous c.1448T>C mutation (p... | ||
Medical condition: Gaucher disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023584-17 | Sponsor Protocol Number: RAS-AZIC | Start Date*: 2012-08-31 | |||||||||||
Sponsor Name:Universität Leipzig | |||||||||||||
Full Title: Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicent... | |||||||||||||
Medical condition: acute myeloid leukeamia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002542-33 | Sponsor Protocol Number: ZYN2-CL-033 | Start Date*: 2022-02-22 | |||||||||||
Sponsor Name:Zynerba Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndro... | |||||||||||||
Medical condition: Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X Messenger Ribonucleoprotein 1 (FMRP), an RNA-binding protein and the gene product of the FMR1 ge... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000586-19 | Sponsor Protocol Number: 307971 | Start Date*: 2005-07-25 |
Sponsor Name:Bayer Schering Pharma AG | ||
Full Title: Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC) | ||
Medical condition: Non small cell lung cancer (NSCLC) stage IIIB or stage IV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-004418-17 | Sponsor Protocol Number: I-BCT-1 | Start Date*: 2014-05-07 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens. | ||
Medical condition: breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001120-54 | Sponsor Protocol Number: SQ167015 | Start Date*: 2016-07-25 |
Sponsor Name:University Hospitals Coventry and Warwickshire NHS Trust | ||
Full Title: Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial Mesenchymal Stem Cells in Women with Recurrent Miscarriage? | ||
Medical condition: Recurrent miscarriage | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003530-13 | Sponsor Protocol Number: 18072011 | Start Date*: 2011-12-20 | |||||||||||
Sponsor Name:Brighton & Sussex University Hospitals NHS Trust | |||||||||||||
Full Title: Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer | |||||||||||||
Medical condition: Primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003689-41 | Sponsor Protocol Number: CRAD001YGB11 | Start Date*: 2012-11-19 |
Sponsor Name:Novartis Pharmaceuticals UK Ltd | ||
Full Title: A Phase IV multicentre, open label study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with everolimus (RAD001) in combination with e... | ||
Medical condition: oestrogen receptor positive breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001217-25 | Sponsor Protocol Number: 2016-001217-25 | Start Date*: 2016-09-07 |
Sponsor Name:Uppsala University | ||
Full Title: Emotion, Serotonin and Premenstrual Dysphoric Disorder (EmSeP) | ||
Medical condition: Premenstrual Dysphoric Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002442-72 | Sponsor Protocol Number: C17-01 | Start Date*: 2017-10-23 | |||||||||||
Sponsor Name:GERCOR | |||||||||||||
Full Title: RECIST 1.1 and iRECIST evaluation for patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab. A GERCOR open-label phase II study NIPICOL C17-01 | |||||||||||||
Medical condition: Patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001447-40 | Sponsor Protocol Number: 28UCS2019 | Start Date*: 2020-06-29 | ||||||||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | ||||||||||||||||||
Full Title: Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | ||||||||||||||||||
Medical condition: Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer in post-menopausal women | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002749-23 | Sponsor Protocol Number: AGMT_MM-1/EMN-13 | Start Date*: 2015-01-19 |
Sponsor Name:AGMT gGmbH | ||
Full Title: Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma | ||
Medical condition: refractory and/or relapsed multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) CZ (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000126-38 | Sponsor Protocol Number: OVG2012/05 | Start Date*: 2014-04-08 |
Sponsor Name:University of Oxford | ||
Full Title: Towards improved meningococcal vaccines: a randomised, descriptive, open label study exploring the relationship between gene expression signatures with reactogenicity and immunogenicity following v... | ||
Medical condition: This study aims to investigate gene expression following vaccination with 4CMenB and relate this to vaccine reactions and to immune response | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-003335-29 | Sponsor Protocol Number: SIOPEATRT01 | Start Date*: 2021-04-15 |
Sponsor Name:German Pediatric Oncology Group, GPOH gGmbH | ||
Full Title: An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including A randomized phase III study evaluating the non-inferiority of three courses of hig... | ||
Medical condition: atypical teratoid/rhabdoid tumours (ATRT) | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) NO (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005088-30 | Sponsor Protocol Number: STOP-LEUKEMIA | Start Date*: 2021-03-26 | |||||||||||
Sponsor Name:Kirsten Grønbæk | |||||||||||||
Full Title: STOP-LEUKEMIA: A pilot study of metformin as a leukemia-preventive drug in patients with CCUS or LR-MDS | |||||||||||||
Medical condition: Clonal cytopenia of undetermined significance (CCUS) and lower-risk myelodysplastic syndrome (LR-MDS). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002262-39 | Sponsor Protocol Number: 131I-IPA-TLX-101-001 | Start Date*: 2018-10-24 |
Sponsor Name:TELIX International Pty Ltd | ||
Full Title: A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I... | ||
Medical condition: 2nd line therapy of recurrent GBM (Glioblastoma multiforme), scheduled for repeat XRT. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) NL (Completed) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001982-26 | Sponsor Protocol Number: OZM-063 | Start Date*: 2018-04-26 | |||||||||||
Sponsor Name:The Hospital for Sick Children | |||||||||||||
Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma... | |||||||||||||
Medical condition: Unresectable or progressive low grade glioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001793-36 | Sponsor Protocol Number: GTX-102-001 | Start Date*: 2023-04-26 |
Sponsor Name:Ultragenyx Pharmaceutical Inc. | ||
Full Title: A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS) | ||
Medical condition: Angelman Syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Ongoing) FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001639-21 | Sponsor Protocol Number: NMDSG10B | Start Date*: 2011-11-01 | |||||||||||
Sponsor Name:NMDSG Nordics Myeloplastics Syndrom Study Group | |||||||||||||
Full Title: A multicentre open randomized phase II study of the efficacy and safety of azacitidine alone or in combination with lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotyp... | |||||||||||||
Medical condition: Myelodysplastic syndrome and acute myeloid leukemia with a deletion of 5q | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) NO (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010390-21 | Sponsor Protocol Number: ML21965 | Start Date*: 2010-02-10 | |||||||||||
Sponsor Name:Roche Pharma AG | |||||||||||||
Full Title: A randomized, open-label, multi-center Phase II trial of bevacizumab and radiotherapy fol-lowed by bevacizumab and irinotecan vs. temozolomide and radiotherapy followed by temo-zolomide monotherapy... | |||||||||||||
Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
